Session II: Cancer of the Pancreas

Chair(s)

• 

  Margaret Tempero, MD

  UCSF
  Lincoln, United States
• 

  Eric Van Cutsem, MD, PhD

  University Hospital Gasthuisberg/Leuven
  Leuven, Belgium

Presentations:

• 13:30 – 13:50

  Hereditary Predisposition to Pancreatic Cancer: Whom and How To Screen and What to Look For?
  

  Speaker: Judith Balmaña, MD – Vall d’Hebron University Hospital
• 13:50 – 14:10

  Management of Pre-Malignant Pancreatic Lesions
  

  Speaker: Pascal R. Hammel, MD – Assistance Publique Hôpitaux de Paris
• 14:10 – 14:18

  SO-1: Clinical and molecular features of patients with KRAS wild-type pancreatic adenocarcinoma
  

  Abstract Presenter: Imen Ben-Ammar
• 14:18 – 14:28

  Debate: Molecular Changes in Pancreatic Ductal Adenocarcinoma: NGS in All Patients With PDAC - PRO
  

  Debate Speaker: Thomas T. Seufferlein, MD, PhD – Ulm University
• 14:28 – 14:38

  Debate: Molecular Changes in Pancreatic Ductal Adenocarcinoma: NGS in All Patients With PDAC - CON
  

  Debate Speaker: Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
• 14:38 – 14:50

  Debate: Molecular Changes in Pancreatic Ductal Adenocarcinoma: NGS in All Patients With PDAC - DISCUSSION
  

  Panelist: Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center

  Panelist: Thomas T. Seufferlein, MD, PhD – Ulm University

  Panelist: Margaret A. Tempero, MD – UCSF

  Panelist: Eric Van Cutsem, MD, PhD – University Hospital Gasthuisberg/Leuven
• 14:50 – 14:58

  SO-2: Comparison of resected vs. non-resected patients with unresectable locally advanced pancreatic cancer (LAPC) receiving P-32 microparticles with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy in the PanCO study
  

  Abstract Presenter: Paul Ross, PhD FRCP – Guy's & St Thomas' NHS Foundation Trust
• 14:58 – 15:35

  Cases With Panel Discussion: Resectable, Borderline Resectable, and Unresectable Pancreatic Cancer
  

  Moderator: Eric Van Cutsem, MD, PhD – University Hospital Gasthuisberg/Leuven

  Moderator: Margaret A. Tempero, MD – UCSF

  Panelist: Gerald Prager, MD – Medizinische Universität Wien

  Panelist: Oliver Strobel, MD, MBA – Medical University of Vienna

  Panelist: Maria Antonietta Bali, MD PhD – Institut Jules Bordet, ULB, HUB

  Panelist: Karin Haustermans, MD, PhD – University Hospital Gasthuisberg
• 15:35 – 15:55

  New Treatment Options in Pancreatic Cancer
  

  Speaker: Philip A. Philip, MD, PhD, FRCP – Wayne State University School of Medicine
• 15:55 – 16:15

  Are We Making Progress in Targeting the Microenvironment and Immune System in PDAC?
  

  Speaker: Eileen M. O'Reilly, MD – Memorial Sloan Kettering Cancer Center